"We would like to thank the U.S. and United Kingdom governments for their substantial support in accelerating the development and production of the vaccine, we will do everything in our power to make this vaccine quickly and widely available".
Hot on the heels of biotech company Moderna's recent announcement of successful phase 1 trials for its mRNA COVID-19 vaccine, two more promising candidates are delivering encouraging early data as several vaccines race into phase 2 human testing. As there is now no vaccine available for coronavirus, but researchers and medicine makers are working on it.It could take a minimum of 18 months to develop.
"Our investment in Novavax allows us to focus on manufacturing in parallel with the clinical development of the vaccine, so that if the vaccine is proven to be safe and effective, we can make doses available to those who need them without delay", CEPI chief executive Richard Hatchett, said in a statement.
The licensing of the vaccine, formerly ChAdOx1 nCoV-19 and now known as AZD1222, follows the recent global development and distribution agreement with the University's Jenner Institute and the Oxford Vaccine Group. About half of the participants in the trial had powerful antibodies to Ad5 before they got the vaccine. That the a number of vaccines transferring into human trials have been constructed utilizing quite a few completely different applied sciences is considered a constructive signal, elevating the likelihood that certainly one of them might succeed.
For a COVID-19 vaccine to be authorised, the EMA has to have strong evidence from clinical trials demonstrating its safety, efficacy and quality.
However, good news has developed regarding efforts toward making a vaccine.
The vaccine, created by Maryland firm Novavax, has been formulated utilizing another technique from the others being developed all over the world.
On the production end, AstraZeneca has concluded its first manufacturing agreements to produce at least 400 million doses of the vaccine, as well as gain total manufacturing capacity for one billion doses so far.
The research team will continue tests on animals, but have made enough progress to start thinking about testing the vaccine on people. "At the moment, there's a 50 per cent chance that we get no result at all".
That's surprisingly low considering the effort going into the global race for a coronavirus vaccine that has sparked a pandemic since the first time it left China late past year.
Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine, said "That may limit the use of this vaccine".